Physician profile
Christopher C Raio
NPI 1255478004
$91,738.51
in general payments reported to CMS, 2019-2025
12 companies · $586 in 2025
The $586 reported for 2025 was more than what 93% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $79K · 2021: $174 · 2022: $273 · 2024: $131 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hyperfine Research, INC. | $74,000.00 | 2020 | |
| Becton, Dickinson and Company | $8,079.21 | 2019 | |
| Bard Access Systems, INC. | $5,188.00 | 2020 | |
| Bard Peripheral Vascular, INC. | $3,187.50 | 2019 | |
| Inari Medical, INC. | $321.36 | 2021-2022 | |
| Octapharma USA, INC. | $276.86 | 2025 | Balfaxar |
| Mindray Ds USA, INC. | $161.68 | 2025 | Te7 Max, Te X |
| Ceribell, INC. | $147.00 | 2025 | Pocket Eeg Device |
| Penumbra, INC. | $130.85 | 2024 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $125.24 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $107.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Raio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.